Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States

References

• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Angulo JC, Valpas A, Rejas J, et al. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig 2014;34:297-307
   PubMed Web of Science ®Google Scholar
• Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm 2014;20:130-40
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2455-63
   PubMed Web of Science ®Google Scholar
• Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;23:2347-58
   PubMed Web of Science ®Google Scholar
• Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
   PubMed Web of Science ®Google Scholar
• Kraus SR, Bavendam T, Brake T, et al. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging 2010;27:697-713
   PubMed Web of Science ®Google Scholar
• Dubeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol 2014;191:395-404
   PubMed Web of Science ®Google Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
   PubMedGoogle Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574-9
   PubMed Web of Science ®Google Scholar
• Chuang C-C, Yang E, Zou K, et al. Health outcomes and functional status of overactive bladder among the medically complex vulnerable elderly in the United States. Poster presentation at American Geriatrics Society 2015 Annual Scientific. Meeting, May 15–17; National Harbor, MD; 2015
   Google Scholar
• Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010;75:526-32, 32 e1-18
   PubMed Web of Science ®Google Scholar
• Chuang C-C, Yang E, Zou K, et al. Healthcare resource utilization and cost of overactive bladder among the medically complex vulnerable elderly in the United States. Poster presentation at American Geriatrics Society 2015 Annual Scientific Meeting, May 15–17; National Harbor, MD; 2015
   Google Scholar
• Nilsson FO, Linner L, Samuelsson E, et al. Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. BJU Int 2012;110:240-6
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Malone DC, Bui CN. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. J Med Econ 2012;15(1 Suppl):35-44
   PubMedGoogle Scholar
• Lunn DJ, Thomas A, Best N, et al. WinBUGS - A Bayesian modelling framework: concepts, structure, and extensibility. Statist Comput 2000;10:325-37
   Web of Science ®Google Scholar
• Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95
   PubMed Web of Science ®Google Scholar
• Sand PK, Heesakkers J, Kraus SR, et al. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging 2012;29:119-31
   PubMed Web of Science ®Google Scholar
• Takei M, Homma Y, Japanese Tolterodine Study G. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 2005;12:456-64
   PubMed Web of Science ®Google Scholar
• Lifford KL, Townsend MK, Curhan GC, et al. The epidemiology of urinary incontinence in older women: incidence, progression, and remission. J Am Geriatr Soc 2008;56:1191-8
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Rejas J, Navarro-Artieda R, et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J 2014;25:485-92
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
   PubMed Web of Science ®Google Scholar
• Goren A, Zou KH, Gupta S, et al. Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy. Int J Clin Pract 2014;68:336-48
   PubMed Web of Science ®Google Scholar
• Bolge S, Cerulli A, Kahler K, et al. Impact of successful treatment of overactive bladder on health care resource use and productivity. Drug Benefit Trends 2006;18:244
   Google Scholar
• Jacobson G, Neuman T, Damico A. Medicare spending and use of medical services for beneficiaries in nursing homes and other long-term care facilities: a potential for achieving Medicare savings and improving the quality of care. The Henry J Kaiser Family Foundation, 2010. Available from: http//kff.org/health-costs/report/medicare-spending-and-use-of-medical-services/ [last accessed 28 Oct 2015]
   Google Scholar
• Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 2010;64:1279-86
   PubMed Web of Science ®Google Scholar
• Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health 2015;19:217-23
   PubMed Web of Science ®Google Scholar
• Sand PK, Steers WD, Dmochowski R, et al. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:667-75
   PubMed Web of Science ®Google Scholar
• Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006;60:745-51
   PubMed Web of Science ®Google Scholar
• Shumway-Cook A, Ciol MA, Hoffman J, et al. Falls in the Medicare population: incidence, associated factors, and impact on health care. Phys Ther 2009;89:324–32
   Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):5s–13s
   Google Scholar
• Unutzer J, Schoenbaum M, Katon WJ, et al. Healthcare costs associated with depression in medically Ill fee-for-service medicare participants. J Am Geriatr Soc 2009;57:506–10
   Google Scholar
• Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997;26:367–74
   Google Scholar